12 April 2018
Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials.
9 April 2018
In this post, Director of Clinical Affairs, Dr Kenton Zavitz, looks at the challenge of recruiting the correct patients into Alzheimer's disease trials.
7 April 2018
Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.
6 April 2018
Our recent review of meta-analyses concluded that facial emotion recognition deficits are common across a range of psychiatric, neurological and developmental disorders.
Our Senior Scientist, Dr Jack Cotter, presented the latest findings at Schizophrenia International Research Society (SIRS) conference.
5 April 2018
Comparing visuospatial associative learning for a middle-aged birth cohort and patients with schizophrenia
Visuospatial memory is extremely heterogeneous in schizophrenia. In a large population study, around a fifth of patients with schizophrenia showed similar errors rates to the top 50% of the general population. Conversely, half of the patients sampled showed substantial impairments.
26 March 2018
The Stockings of Cambridge (SOC) and One-Touch Stockings of Cambridge (OTS) tasks both assess the processes involved in spatial planning, but which is more appropriate for different participant groups? It all depends on the absence or presence of cognitive or motor impairments.
7 March 2018
The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development.